These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 21596680)

  • 21. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
    Torriani FJ; Komarow L; Parker RA; Cotter BR; Currier JS; Dubé MP; Fichtenbaum CJ; Gerschenson M; Mitchell CK; Murphy RL; Squires K; Stein JH;
    J Am Coll Cardiol; 2008 Aug; 52(7):569-76. PubMed ID: 18687253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The per-protocol effect of immediate versus deferred antiretroviral therapy initiation.
    Lodi S; Sharma S; Lundgren JD; Phillips AN; Cole SR; Logan R; Agan BK; Babiker A; Klinker H; Chu H; Law M; Neaton JD; Hernán MA;
    AIDS; 2016 Nov; 30(17):2659-2663. PubMed ID: 27782964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
    Fätkenheuer G; Duvivier C; Rieger A; Durant J; Rey D; Schmidt W; Hill A; van Delft Y; Marks S;
    J Antimicrob Chemother; 2012 Mar; 67(3):685-90. PubMed ID: 22210755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of Ventriculoperitoneal Shunt Surgery in Human Immunodeficiency Virus-Positive Patients on Combination Antiretroviral Therapy with Tuberculosis Meningitis and Hydrocephalus.
    Harrichandparsad R; Nadvi SS; Suleman Moosa MY; Rikus van Dellen J
    World Neurosurg; 2019 Mar; 123():e574-e580. PubMed ID: 30529520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV.
    Pelchen-Matthews A; Mocroft A; Ryom L; Ross MJ; Sharma S; Coca S; Achhra A; Cornell E; Tracy R; Phillips A; Alonso MM; Toulomi G; Agan BK; Medland N; Wyatt CM;
    Kidney Int; 2024 Jul; 106(1):136-144. PubMed ID: 38697479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse events in Chinese human immunodeficiency virus (HIV) patients receiving first line antiretroviral therapy.
    Dai L; Su B; Liu A; Zhang H; Wu H; Zhang T; Shao Y; Li J; Ye J; Bai S; Guo X; Sun L
    BMC Infect Dis; 2020 Feb; 20(1):158. PubMed ID: 32075584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
    DeJesus E; McCarty D; Farthing CF; Shortino DD; Grinsztejn B; Thomas DA; Schrader SR; Castillo SA; Sension MG; Gough K; Madison SJ;
    Clin Infect Dis; 2004 Aug; 39(3):411-8. PubMed ID: 15307010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
    Squires K; Lazzarin A; Gatell JM; Powderly WG; Pokrovskiy V; Delfraissy JF; Jemsek J; Rivero A; Rozenbaum W; Schrader S; Sension M; Vibhagool A; Thiry A; Giordano M
    J Acquir Immune Defic Syndr; 2004 Aug; 36(5):1011-9. PubMed ID: 15247553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial.
    Davis AG; Wasserman S; Stek C; Maxebengula M; Jason Liang C; Stegmann S; Koekemoer S; Jackson A; Kadernani Y; Bremer M; Daroowala R; Aziz S; Goliath R; Lai Sai L; Sihoyiya T; Denti P; Lai RPJ; Crede T; Naude J; Szymanski P; Vallie Y; Banderker IA; Moosa MS; Raubenheimer P; Candy S; Offiah C; Wahl G; Vorster I; Maartens G; Black J; Meintjes G; Wilkinson RJ
    Clin Infect Dis; 2023 Apr; 76(8):1412-1422. PubMed ID: 36482216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.
    Erlandson KM; Fiorillo SP; Cardoso SW; Riviere C; Sanchez J; Hakim J; Kumarasamy N; Badal-Faesen S; Lalloo U; Kumwenda J; Campbell TB; Brown TT
    AIDS Res Hum Retroviruses; 2017 Sep; 33(9):929-934. PubMed ID: 28403619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
    ; Ratsela A; Polis M; Dhlomo S; Emery S; Grandits G; Khabo P; Khanyile T; Komati S; Neaton JD; Naidoo LC; Magongoa D; Qolohle D
    J Infect Dis; 2010 Nov; 202(10):1529-37. PubMed ID: 20942650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV/AIDS.
    Azevedo LN; Ximenes RAA; Monteiro P; Montarroyos UR; Miranda-Filho DB
    Braz J Infect Dis; 2020; 24(1):65-72. PubMed ID: 31835018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
    J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
    Sinha S; Gupta K; Tripathy S; Dhooria S; Ranjan S; Pandey RM
    BMC Infect Dis; 2017 Dec; 17(1):761. PubMed ID: 29228918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
    Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
    Cohen CJ; Molina JM; Cahn P; Clotet B; Fourie J; Grinsztejn B; Wu H; Johnson MA; Saag M; Supparatpinyo K; Crauwels H; Lefebvre E; Rimsky LT; Vanveggel S; Williams P; Boven K; ;
    J Acquir Immune Defic Syndr; 2012 May; 60(1):33-42. PubMed ID: 22343174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.
    Lartey M; Sagoe KW; Yang H; Kenu E; Xexemeku F; Oliver-Commey J; Boima V; Seshie M; Sagoe A; Mingle JA; Flanigan TP; Wu H; Kwara A
    Clin Infect Dis; 2011 Feb; 52(4):547-50. PubMed ID: 21252140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.